Market Cap | 96.83M | P/E | - | EPS this Y | 15.60% | Ern Qtrly Grth | - |
Income | -87.3M | Forward P/E | -1.16 | EPS next Y | -2.90% | 50D Avg Chg | -20.00% |
Sales | 1.66M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -23.00% |
Dividend | N/A | Price/Book | 0.61 | EPS next 5Y | - | 52W High Chg | -52.00% |
Recommedations | 1.70 | Quick Ratio | 11.41 | Shares Outstanding | 47.55M | 52W Low Chg | 23.00% |
Insider Own | 13.24% | ROA | -31.40% | Shares Float | 30.29M | Beta | 2.13 |
Inst Own | 60.01% | ROE | -54.42% | Shares Shorted/Prior | 1.80M/1.65M | Price | 2.28 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 27,174 | Target Price | 15.75 |
Oper. Margin | -2,612.19% | Earnings Date | May 7 | Volume | 13,309 | Change | -0.87% |
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Needham | Buy | Apr 9, 24 |
Needham | Buy | Mar 1, 24 |
HC Wainwright & Co. | Buy | Mar 1, 24 |
HC Wainwright & Co. | Buy | Feb 13, 24 |
Needham | Buy | Feb 13, 24 |
HC Wainwright & Co. | Buy | Aug 11, 23 |
Needham | Buy | Aug 11, 23 |
Needham | Buy | Jun 6, 23 |
HC Wainwright & Co. | Buy | Jun 6, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Golumbeski George | Director Director | Apr 21 | Buy | 3.68 | 26,283 | 96,721 | 26,283 | 04/26/22 |
Schreiber Taylor | Chief Executive Offi.. Chief Executive Officer | Jan 28 | Option | 4.67 | 3,926 | 18,334 | 17,052 | 01/31/22 |
Brous Tyler | Director Director | Jan 14 | Buy | 7.01 | 8,000 | 56,080 | 229,672 | 01/19/22 |
Thomson Erin Ator | General Counsel General Counsel | Jan 10 | Option | 2.95 | 10,000 | 29,500 | 79,084 | 01/12/22 |